A Phase /a Clinical Study of GEN-725 in Combination With Dositinib
Status:
RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label phase I/phase II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GEN-725 in combination with Dositinib in participants with locally advanced or metastatic EGFR-mutant non-small cell lung cancer.